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OBJECTIVES We assessed the extent and the time course of the acute phase response following myocardial
cell necrosis and its relationship with the presence of preinfarction unstable angina (UA).
BACKGROUND Elevated levels of acute phase proteins have been reported in patients with UA and in patients
with acute myocardial infarction (MI).
METHODS C-Reactive Protein (CRP), serum amyloid A protein (SAA) and interleukin-6 (IL-6) were
measured in 36 patients with MI admitted within 3 h from symptoms onset. All patients had
normal levels of creatine kinase and of troponin T on admission, rising above diagnostic levels
within 6 to 12 h. Blood samples for CRP, SAA and IL-6 measurements were taken on
admission, at 6, 24, 48, 72 h and at discharge.
RESULTS Twenty of the 36 patients studied presented an unheralded MI (Group 1); the remaining 16
patients had symptoms of unstable angina in the preceding 7 days (Group 2). Group 2
patients have much higher levels of CRP and SAA on admission (median values 8.8 vs. 3
mg/L and 28 vs. 3.4 mg/L, respectively, all p , 0.001). Following the necrotic insult, despite
similar infarct size and clinical signs of reperfusion, Group 2 patients had strikingly higher
peaks of IL-6 (median values 85.2 vs. 19 pg/ml, p , 0.05), CRP (50 vs. 31.4 mg/L, p , 0.05)
and SAA (228 vs. 45 mg/L, p , 0.001).
CONCLUSIONS Our data demonstrated that the acute phase response is greatly enhanced in patients with
preinfarction UA compared with those presenting with an unheralded MI. The significant
differences in acute phase response observed in these two clinical presentations of MI indicate
a major difference in their underlying pathogenetic components. (J Am Coll Cardiol 1999;
34:1696–703) © 1999 by the American College of Cardiology
Recently, the observation of inflammatory infiltrates in
unstable coronary plaques (1–3) and the presence of acti-
vated circulating neutrophils (4–6), lymphocytes (7,8) and
monocytes (9,10) have suggested that inflammatory
stimuli may contribute to the pathogenesis of acute coronary
syndromes. Furthermore, increased concentrations of
C-reactive protein (CRP) and serum amyloid A protein
(SAA), highly sensitive acute phase reactants and
interleukin-6 (IL-6), a proinflammatory cytokine which is
the major determinant of acute phase protein production,
have been reported in patients with unstable angina (UA)
(11–14) and in patients with acute myocardial infarction
(MI) at the time of hospital admission (12,15).
However, the triggers of the acute persistent thrombotic
occlusion responsible for (MI) may be multiple. In a
previous study we have found that a substantial proportion
of patients presenting with totally unheralded MI had
normal CRP and SAA levels, in striking contrast with
patients with preinfarction UA (12).
Thus, in this study we measured plasma levels of CRP,
SAA and IL-6 in 36 patients with documented MI admit-
ted within 3 h from symptom onset. Our findings demon-
strate that the acute phase response on admission and
following MI is significantly greater in patients with prein-
farction UA than in those with unheralded MI, suggesting
that these two clinical presentations of MI might be
associated with different pathogenetic components of acute
coronary occlusion.
METHODS
Patient population. Thirty-six of the 158 consecutive
patients admitted to our coronary care unit between Octo-
ber 1993 and October 1994 with a diagnosis of possible
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acute MI were included into the study (27 men; mean age
61 6 10 yr).
Inclusion criteria were: typical chest pain lasting .30 min;
ST-segment elevation $0.2 mV in $2 contiguous leads of the
standard 12-lead ECG, resistant to a 2 to 4 mg intravenous
bolus of isosorbide dinitrate; admission within 3 h from onset
of prolonged chest pain and normal serum creatine kinase
(CK) (reference range 30 to 230 IU per liter) and troponin T
(,0.1 mg/l) on admission rising above diagnostic levels (i.e.
two times the upper limit of normal and .0.5 mg/l, respec-
tively) within 6 to 12 h. Exclusion criteria were: admission
more than 3 h from onset of symptoms (48 patients, in 29 of
whom CK was already elevated), a previous myocardial MI
within 6 months (18 patients), contraindications to thrombo-
litic therapy (16 patients), left bundle branch block or atrial
fibrillation (15 patients), chronic dissecting aortic aneurysm (5
patients), inflammatory conditions likely to be associated with
an acute phase response (12 patients), and neoplastic disease
(8 patients).
All patients received intravenous thrombolitic agents,
streptokinase (SK) 1.5 million units as a continuous infusion
over 60 min (26 patients) or rt-PA 15 mg as bolus followed
by 50 mg as a continuous infusion over 30 min and 35 mg
in 60 min (10 patients), according to the physician’s
judgment. An intravenous infusion of isosorbide dinitrate
was started at a rate of 1 to 10 mg/h, titrated against systolic
blood pressure and continued for 24 to 48 h as clinically
required. All patients also received oral aspirin (100 mg/day);
30 patients received an intravenous infusion of heparin over
the first 24 h adjusted four-hourly to achieve an activated
partial thromboplastin time between two and three times
the control value; and 18 patients were also treated with oral
calcium-channel blockers and 12 with oral beta-adrenergic
blocking agents. Coronary angiography was performed in
26 patients within five to seven days from admission.
Within 24 h from admission, the patients were classified
as having either an unheralded MI or UA in the week
preceding their MI. Unheralded MI was defined as a single
episode of prolonged chest pain in patients without previous
history of ischemic heart disease or in patients with previous
history of chronic stable angina, but no acute events or
worsening of symptoms in the last 6 months. Preinfarction UA
was defined as $2 episodes of angina at rest lasting ,30 min
in the seven days preceding the MI, documented ST-segment
shift diagnostic for myocardial ischemia during the angina
attacks, the last episode of chest pain in the last 48 h.
The Ethics Committee of the Catholic University of Rome
approved the protocol; all patients gave informed consent.
Study protocol. Blood sampling. Blood samples were taken
from an antecubital vein as soon as possible after the
Coronary Care Unit admission, before the intravenous
administration of drugs, and subsequently, at 6, 24, 48, 72 h
and at discharge. Coded plasma samples were stored at
270° C and analyzed for CRP, SAA and IL-6 in a single
batch at the end of the study; all categorization and
management of patients were independent of these results.
In addition, six-hourly blood samples for the plasma deter-
mination of total CK were collected during the first 24 h
from admission and at 48 h. Finally, troponin T, a specific
marker of myocardial necrosis, was measured on admission
and 6 and 12 h later.
Estimation of infarct size and noninvasive assessment of
reperfusion. Infarct size was estimated from peak CK level,
from the area under the 48-h CK time-concentration curve
and from the predischarge evaluation of left ventricular
ejection fraction (EF) and global wall motion score (WMS)
assessed by echocardiography. The success of the thrombo-
litic treatment was assessed using noninvasive markers of
reperfusion: the time to peak CK level and a reduction
greater than 50% in the sum of ST elevation (in the leads
showing .1 mm ST elevation) at 4 h from the start of the
thrombolysis (16).
Laboratory assays. C-reactive protein and SAA were as-
sayed by an automated monoclonal antibody solid phase
sandwich-type enzyme immunoassay on the Abbott IMX
instrument (Abbott Laboratories, Chicago, Illinois), as
previously described (12). The median normal value for
CRP is 0.8 mg/L, with 90% of normal values ,3 mg/L.
C-reactive protein levels begin to rise 6 h after an acute
stimulus and peak after 24–48 h; the half-life of CRP in the
circulation is 19 h (17). The median (range) normal SAA
concentration is 3 (0.7 to 26.4), with 82% less than 5 mg/L.
Circulating concentrations of SAA can increase from nor-
mal, about 5 mg/L, to .1,000 mg/L within 24 to 48 h of
an acute stimulus (17).
Interleukin-6 was measured with a commercial assay kit
(Quantikine human IL-6 R&D System, Minneapolis, Min-
nesota). Interleukin-6 measurements were performed in dupli-
cate, and the intra- and interassays variability was less than
10%. The range of values detected by the assay is 3 to
300 pg/ml. Interleukin-6 levels begin to rise 45 to 60 min after
endotoxin injection in healthy volunteers and peak after 2 to
4 h (18). Interleukin-6 half-life in the circulation was calcu-
lated to be around 4 h (19).
Troponin T was measured with a commercial enzyme
immunoassay kit (Boehringer Mannheim, Mannheim, Ger-
many).
Abbreviations and Acronyms
CAD 5 coronary artery disease
CI 5 confidence interval
CK 5 creatine kinase
CRP 5 C-reactive protein
EF 5 ejection fraction
IL-6 5 interleukin-6
MI 5 myocardial infarction
SAA 5 serum amyloid A protein
SK 5 streptokinase
UA 5 unstable angina
WM 5 wall motion score
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Statistics. Because CRP, SAA and IL-6 values do not
follow a normal distribution, comparisons between groups
were carried out using the Mann-Whitney U test. Compar-
isons within groups were carried out using the Friedman
test; for a p value of ,0.05, pairwise comparisons were
carried out using the Wilcoxon test with the Bonferroni
correction. Correlations were determined using Spearman’s
rank correlation test. The remaining continuous variables
were compared using t tests for paired and unpaired
variables, as appropriate. Proportions were compared using
the chi-square test. C-reactive protein, SAA and IL-6
values are expressed as median and range, the remaining
variables are expressed as mean 6 standard deviation; p
values ,0.05 (two-tailed) were considered statistically
significant.
RESULTS
Of the 36 patients enrolled, 20 had a totally unheralded
MI; in 15 MI was the very first manifestation of coronary
artery disease, 5 of them had a history of chronic stable angina
but without worsening of symptoms before the acute event
(Group 1). The remaining 16 patients had symptoms of
severe UA (Braunwald class IIIB) in the preceding 7 days
(Group 2).
In Group 2, symptoms of UA started 2 to 18 days before
MI, on average 9.8 6 5 days. There were 79 episodes of
angina at rest before the MI, which accounted for a mean of
5.3 6 2 angina episodes per patient (range 2 to 9). The time
interval between the last episode and the onset of MI was
19 6 10 h (range 2 to 36 h). In 11 patients of this group,
UA was the first manifestation of coronary artery disease.
The two groups did not otherwise differ significantly in
baseline characteristics (Table 1).
Infarct size. At the time of Coronary Care Unit admis-
sion, troponin T and CK were normal in all samples.
During the subsequent 6 to 24 h, the cardiac enzymes
reached a diagnostic level for myocardial cell necrosis in all
patients.
The three indexes used for the estimation of infarct size
(peak total CK, predischarge left ventricular EF and global
WMS assessed by echocardiography) were similar in the
two groups of patients (Table 1, Fig. 1). The success of the
thrombolitic treatment, assessed using time to peak CK
level and a reduction greater than 50% in the sum of ST




(n 5 16) p Value
Age, years, mean 6 SD 59 6 9 65 6 10 0.13
Gender (M/F) 14/6 13/3 0.7
Risk factors; n. of patients (%):
- Family history of CAD 10 (50) 4 (25) 0.24
- Hypercholesterolemia 7 (35) 4 (25) 0.78
- Diabetes 7 (35) 1 (6) 0.1
- Hypertension 5 (20) 7 (44) 0.47
- Smoking 15 (75) 12 (75) 0.7
Previous history; n. of patients (%):
- Chronic stable angina 5 (25) 1 (6) 0.29
- Previous MI (.6 months) 2 (10) 4 (25) 0.45
Interval between onset of symptoms
and admission (min)
132 6 47 106 6 63 0.16
Thrombolytic therapy; n. of patients (%):
- SK 16 (80) 10 (63) 0.43
- rtPA 4 (20) 6 (37) 0.43
Infarct site; n. of patients (%):
- Anterior 6 (30) 9 (56) 0.21
- Inferior 12 (60) 7 (44) 0.53
- Lateral 2 (10) 0 0.57
Infarct size:
- Peak CK level (IU/L) 1,932 6 1,496 1,654 6 967 0.52
- Predischarge EF (%) (Echo) 46 6 9 44 6 7 0.39
- Predischarge WM score (Echo) 8 6 6 7.4 6 5 0.73
Noninvasive markers of reperfusion:
- Time to peak CK level (h) 16 6 6.5 11.6 6 6.4 0.057
- Patients with a reduction in ST sum
elevation $50% at 4 h (%)
11 (55) 13 (81) 0.19
CAD 5 coronary artery disease; CK 5 creatine kinase; EF 5 ejection fraction; MI 5 myocardial infarction; SK 5 streptokinase;
WM score 5 wall motion score.
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elevation at 4 h from the start of the thrombolysis, was also
similar (Table 1).
Inflammatory response to myocardial cell necrosis. Un-
heralded MI. On admission, plasma levels of IL-6 were
detectable only in 9/20 (45%) patients, all of whom also had
elevated levels of CRP and five also had elevated levels of
SAA. Plasma concentrations of CRP and SAA were normal
(,3 mg/L and ,5 mg/L, respectively) in 11 patients (55%).
Median CRP and SAA values were 3 and 3.4 mg/L,
respectively (Table 2, Fig. 2). No difference was found in
baseline CRP and SAA levels between the 15 patients of
Group 1 in whom MI was the very first manifestation of
coronary artery disease (CAD) and the five patients with
previous history of chronic stable angina. In response to
myocardial cell necrosis, IL-6 median levels in Group 1
showed a slight but not significant increase (p 5 0.16)
(Table 2, Fig. 3); the median levels of CRP and SAA
significantly increased with a peak at 48 h and 72 h,
respectively (all p , 0.01) (Table 2, Fig. 4).
Preinfarction unstable angina. On admission, IL-6 levels
were detectable in 14/16 patients (88%, p 5 0.014 vs. Group
1) and CRP or SAA were elevated in all patients (p 5 0.002
vs. Group 1); CRP was 8.8 mg/L and SAA was 28 mg/L (all
p , 0.001 vs. Group 1) (Table 2, Fig. 2). No correlation was
found between the number and the mean duration of ischemic
episodes in the week preceding the MI and baseline levels of
acute phase reactants. The serum concentration of IL-6 sig-
nificantly increased 6 h later (p 5 0.010) and reached the peak
value at 24 h (p 5 0.005 vs. baseline, p 5 0.36 vs. 6 h) (Table
2, Fig. 3). Also CRP and SAA showed a marked increase, with
a peak value at 48 h (all p , 0.001) (Table 2, Fig. 4). There was
a significant correlation between the peak values of IL-6 and
those of CRP and SAA [r 5 0.48, 95% confidence interval
(CI) 5 0.12 to 0.71, p , 0.001 and r 5 0.68, p , 0.001, 95%
CI 5 0.40 to 0.84, respectively].
Thus, Group 2 patients showed a strikingly higher acute
phase response during the study period than Group 1
patients. Interleuken-6 levels were significantly higher in
Group 2 than in Group 1 at 6 and 24 h, CRP at 6, 24 and
48 h and SAA at 6, 24, 48 and 72 h (Table 2).
Correlation between baseline and peak levels of CRP and
SAA after myocardial cell necrosis. In order to investigate
whether the inflammatory response observed after MI was
related to the baseline levels of CRP and SAA, we corre-
lated baseline and peak levels of CRP and SAA using the
Spearman’s rank correlation test. In the overall population
of 36 patients, there was a significant, close correlation
between the baseline levels of CRP and SAA and the
respective increases after MI (r 5 0.55 and r 5 0.65,
respectively; all p , 0.001) (Fig. 5).
When the increase of CRP and SAA was normalized for
the peak level of CK, Group 2 patients still showed a
significantly higher acute phase response than Group 1
patients. C-reactive protein increase normalized for CK
peak level [(peak CRP/peak CK) 3 100] was 2.6 (0.3 to
13.6) in Group 1 and 5 (2.4 to 19.7) in Group 2 (p 5 0.03);
SAA increase normalized for CK peak level [(peak SAA/
peak CK) 3 100] was 6.4 (0.5 to 53.7) in Group 1 and 14.8
(8.1 to 73.4) in Group 2 (p 5 0.019).
Table 2. Plasma Levels of CRP and SAA and Serum Levels of IL-6 During the Study Period
Entry 6 h 24 h 48 h 72 h Discharge
CRP (mg/L)
GROUP 1 3 (2.4–8.9) 4.2 (2.4–14.3)* 27.2 (2.8–161)* 31.4 (6.7–125)* 21.9 (4.8–65.3)* 6.7 (2.4–20) p 5 0.003
GROUP 2 8.8 (4.4–69.8)§ 17.7 (7.6–75.4)†§ 46.2 (7.7–256)†‡ 50 (13.7–158)†‡ 34.7 (10–116)* 14.2 (3.3–73) p 5 0.002
SAA (mg/L)
GROUP 1 3.4 (0.7–7.9) 5.4 (1.3–203)* 30.5 (3.4–249.9)* 37.7 (5.7–295)* 45 (4.7–312)* 5.4 (0.8–31.1) p , 0.001
GROUP 2 28 (3.2–282.4)§ 38.3 (58–968)*§ 191 (29.2–992)†§ 228 (4.2–597)†§ 207 (3.7–386.9)†§ 27 (2.6–197.9) p , 0.001
IL-6 (pg/ml)
GROUP 1 3.9 (0–34.2) 12.8 (0–37.5) 19.1 (0–100) 10.2 (0–78.9) 5.9 (0–53.3) 3.5 (0–11.1) p 5 0.16
GROUP 2 12.5 (0–74.4) 44.6 (12.5–172)*‡ 85.2 (9–393.3)*‡ 18.2 (3–296.5) 12.9 (0–138.3) 5.6 (0–12.5) p 5 0.013
Data are presented as median (range). CRP 5 C-reactive protein; IL-6 5 interleukin-6; SAA 5 serum amyloid A protein. Group 1 5 20 patients with unheralded myocardial
infarction; Group 2 5 16 patients with preinfarction unstable angina. *p , 0.05 vs. entry; †p , 0.001 vs. entry; ‡p , 0.05 vs. Group 1; §p , 0.001 vs. Group 1.
Figure 1. Plasma CK values. Data are presented as mean and
standard error. Unheralded MI (open circle) (Group 1), pre-
infarction UA (solid circle) (Group 2). Plasma CK values did not
significantly differ in the 2 groups of patients. CK 5 creatine
kinase; MI 5 myocardial infarction; UA 5 unstable angina.
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DISCUSSION
Our findings demonstrate that the acute phase response is
greatly enhanced in patients with preinfarction UA com-
pared with those presenting with a totally unheralded MI.
They had much higher levels of CRP and SAA before the
event and also strikingly higher peaks of IL-6, CRP and
SAA following the necrotic insult, despite similar infarct
size and clinical signs of reperfusion. The consistently
elevated levels of CRP and SAA in all patients with
preinfarction UA, but only in 45% of patients with unher-
alded MI, confirm previous data from our group (12), and
the observation that monocytes activation was observed at
the time of hospital admission in UA but not in acute MI
(10). These conspicuous differences in acute phase response
observed in these two subgroups suggest that the different
clinical presentation, i.e. unheralded MI and UA may be
related to different pathogenetic components.
Preinfarction acute phase response. The elevation of
baseline levels of acute phase proteins in patients with UA
cannot be attributed to the severity of atherosclerosis, as
there is no correlation between the degree of atherosclerosis
and the acute phase response in patients with chronic stable
angina or peripheral vascular disease, in spite of much more
extensive atherosclerotic and thrombotic involvement (12).
It cannot be attributed to episodic activation of the hemo-
static system because the systemic elevation of markers of
thrombin production is not followed by further elevation of
acute phase proteins (20), nor can it be attributed to
ischemia-reperfusion injury, as circulating neutrophils were
not activated and CRP levels were not increased in patients
with variant angina (6,21). Indeed, about 45% of patients
with Braunwald’s class IIIB UA have CRP levels above the
normal range 3 months after hospital discharge, and the risk
of recurrent episodes of instability and of MI within 1 year
is greatly increased in such patients (22). This observation is
in line with the long-term prognostic value of elevated CRP
levels in patients with known ischemic heart disease (13)
and in apparently healthy subjects with (23,24) or without
(25) high levels of risk factors.
Several autoantigens expressed in the atherosclerotic
plaque are able to elicit an inflammatory response, including
oxidized LDL and heat shock proteins (26,27). Infectious
agents have been detected in advanced coronary atheroscle-
rotic lesions and associated to the risk of ischemic heart
disease in several epidemiological studies and could be
responsible for the acute phase response (28).
The observation that no elevation of IL-6, CRP or SAA
was detectable in about one half of the cases presenting with
a totally unheralded MI suggests that MI can develop also
in the absence of any detectable acute phase response. On
the other hand, some cases of unheralded MI could have
been preceded by undetected or silent UA.
Postinfarction acute phase response. Myocardial cell ne-
crosis is well recognized as a powerful proinflammatory
stimulus (29,30). Experimental studies have shown that
periods of ischemia as short as 15 min followed by reper-
fusion elicit a cascade of proinflammatory reactions that
include production of oxygen-derived free radicals (31),
Figure 3. Changes in serum levels of IL-6 in response to myocar-
dial cell necrosis. Data are presented as medians. Unheralded MI
(open box) (Group 1), preinfarction UA (solid box) (Group 2). In
Group 1, IL-6 median levels showed a slight but not significant
increase in response to myocardial cell necrosis. In Group 2, in
contrast, the serum concentration of IL-6 significantly increased at
6 h, reaching the peak value at 24 h. IL-6 5 interleukin-6.
Figure 2. Plasma levels of CRP (Panel A) and SAA (Panel B) at the time of hospital admission. On admission, within 3 h from onset
of prolonged chest pain, patients with preinfarction UA had significantly higher levels of CRP and SAA than patients with unheralded
MI (all p , 0.001). CRP 5 C-reactive protein; MI 5 myocardial infarction; SAA 5 serum amyloid A protein; UA 5 unstable angina.
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activation of the complement system, adhesion molecule
expression, adherence of neutrophils to the coronary endo-
thelium and cardiac myocytes (32), leukocyte-mediated
injury of the myocardial cells (33) and production of
cytokines (34), including IL-6 and IL-1, which are the
major determinants of acute phase protein production
(35,36). In patients, neutrophil activation with signs of
endothelial injury and release of proinflammatory cytokines
has been demonstrated in acute MI (29,30) and after
coronary angioplasty (37).
Several studies investigated the acute phase response and
the kinetics of proinflammatory citokines in patients after
acute MI (38–41). The magnitude of the acute phase
response was found directly correlated with short- and
long-term prognosis after MI (12,42–44). However, in
many of these studies, particularly in patients treated with
early thrombolysis, no correlation was found between infarct
size and extent of the acute phase response (12,15,42,43).
Thus, the mechanisms that may relate the blood level of
acute phase proteins to acute coronary syndromes are still
only partially known.
In our study, we observed a typical acute phase response
of CRP and SAA following myocardial cell necrosis with an
early peak of IL-6 followed by CRP and SAA peaks.
However, the acute phase response was strikingly greater in
patients with preinfarction UA than in those with totally
unheralded MI. As the two groups did not differ signifi-
cantly in estimated infarct size and clinical signs of reper-
fusion, we can hypothesize that the nature and intensity of
the stimuli provoked by myocardial cell necrosis and by
reperfusion were similar in the two groups of patients. Thus,
patients with preinfarction UA may be more responsive
than patients with unheralded MI to the inflammatory
stimuli caused by myocardial necrosis and reperfusion, and
elevated baseline levels of acute phase reactants may be
markers of such hyper responsiveness. A genetically deter-
mined variability of response was reported for cytokine
production by human monocytes following endotoxin stim-
ulation in vitro (45) and for inflammatory responses to
oxidized lipoproteins in inbred mouse strains (46). Alterna-
tively, monocytes and granulocytes of patients with prein-
farction UA and elevated levels of IL-6, CRP and SAA may
be “primed” to produce more cytokines and reactive oxygen
species in response to subliminal stimuli (47–49). The
Figure 4. Changes in plasma levels of CRP (Panel A) and SAA (Panel B) in response to myocardial cell necrosis. Data are presented as
medians. Unheralded MI (open box) (Group 1), preinfarction UA (solid box) (Group 2). Group 2 patients showed a striking higher acute
phase response during the study period than Group 1 patients. C-reactive protein levels were significantly higher in Group 2 than in Group
1 at 6, 24 and 48 h and SAA levels at 6, 24, 48 and 72 h. Abbreviations as in Figure 2.
Figure 5. Correlation between baseline and peak levels of CRP (Panel A) and SAA (Panel B) after myocardial cell necrosis. Unheralded
MI (open circle) (Group 1), preinfarction UA (solid circle) (Group 2). In the overall population of 36 patients, there was a significant
correlation between the baseline levels of CRP and SAA and the respective increases after MI (r 5 0.55, 95% CI 0.27–0.75 and r 5 0.65,
95% CI 0.40–0.82, respectively; all p , 0.001). CI 5 confidence interval. All other abbreviations as in Figure 2.
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hypothesis of an enhanced individual acute phase respon-
siveness is supported by two observations. First, when the
increase of CRP and SAA was normalized for the peak level
of CK, Group 2 patients still showed a significantly higher
acute phase response than Group 1 patients. Second, we
found a positive correlation between baseline and peak
values of acute phase reactants not only following MI, but
also following percutaneous transluminal coronary angio-
plasty and following uncomplicated cardiac catheterization
and coronary angiography (50).
This interpretation is consistent with our recent observa-
tion that monocytes of unstable patients are hyper respon-
sive to lypopolysaccharide challenges in vitro (51).
The acute phase hyper responsiveness, if confirmed, may
contribute to explaining the strong positive correlation
between baseline CRP values within the normal range and
the incidence of MI over an eight-year follow-up in the
Physician’s Health Study (25) and the long-term prognostic
value of elevated CRP levels in patients with known
ischemic heart disease (13,22) and with high levels of risk
factors (23,24). Thus, individuals with an enhanced acute
phase response to low-grade stimulation by chronic infec-
tion, oxidized LDL and to other inflammatory stimuli may
be at increased risk of UA and of its evolution towards MI
in the short- or long-term (12,22).
It may look surprising that patients with preinfarction
UA have high levels of CRP at baseline and a strikingly
higher increase of CRP after MI. As in other studies
preinfarction angina was associated with better outcomes
(52,53) and CRP was almost uniformly associated with
worse outcomes (12,13,22–25,42–44). However, the ques-
tion we addressed in our study was neither the prognostic
importance of CRP (although it is evident in our study, as
indeed patients with baseline high levels of CRP and UA
develop an acute MI) nor the protective effect of having
preinfarction angina. We found an increased acute phase
response following necrotic insult in patients with prein-
farction UA and high CRP levels at baseline as compared
with those with totally unheralded MI (the 55% of whom
had normal baseline levels of CRP). This is in agreement
with our recent observation that patients with UA and
raised levels of CRP have an enhanced acute phase response
following percutaneous transluminal coronary angioplasty as
compared not only with stable angina patients but also with
patients with UA and normal levels of CRP (50). These
observations are not in contrast with the possibility that
patients with preinfarction UA and low CRP, although in
our experience rarer, might have low CRP after the MI and
a better clinical outcome.
Conclusion. Our findings suggest that the causes respon-
sible for the progression from UA to infarction may differ
from those triggering unheralded infarction. This possibility
may have clinical implications, as different precipitating
causes may not equally benefit from the same therapeutic
and preventive approach nowadays applied indiscriminately
to all patients with acute MI (54).
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